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Introduction Our previous studies demonstrated that a high bone turnover state under osteoporotic changes 
decreased the threshold of skeletal pain. Recent studies reported that the incidence of joint pain due to osteoarthritis 
(OA) in postmenopausal women was higher than that in males even with the same radiographic OA grade. The aim 
of this study was to evaluate whether a high bone turnover state affects the induction of pain-like behaviors in mild 
OA model mice.  
Method We established mild OA model mice with accompanying osteoporotic changes by monosodium iodoacetate 
injection after ovariectomy. We assessed pain-like behaviors by von Frey test and paw-flick test; histological changes 
in OA joints; the expression of Runx2, Osterix, Osteocalcin, and Rankl; bone micro-architecture by µCT and 
measured serum tartrate-resistant acid-phosphatase 5b levels in the model mice. 
Results Pain-like behaviors in mice with OA and osteoporotic changes were significantly increased in comparison 
with those in OA mice without osteoporotic changes. The severity of histological OA changes did not differ 
significantly between the OA mice with and without osteoporotic changes. Bisphosphonate significantly improved 
pain-like behaviors accompanied with improvement in the high bone turnover state in the OA mice with osteoporosis, 
while it had no significant effect on pain-like behaviors in the OA mice without osteoporosis. In addition, the 
improvement was maintained for more than 4 weeks even after the discontinuation of bisphosphonate treatment 
Conclusion These results indicated that a high bone turnover state under osteoporotic changes could affect the 
induction of pain-like behaviors in mild OA model mice. 
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Osteoporosis is characterized by a high bone turnover state with decreased bone mass and increased risk of 
fragility fracture in postmenopausal patients [1]. The number of patients with osteoporosis is estimated at 12,800,000 
in Japan [2,3]. Osteoarthritis (OA) is characterized by pathologic features including joint space narrowing and 
osteophytosis, and represents a major public health issue associated with chronic skeletal pain in the elderly [4]. The 
number of patients with radiographic knee OA is estimated at 25,300,000 in Japan [3]. The proportion of patients 
with osteoporosis or OA increases with age, with the incidence of osteoporosis, in particular, increasing in 
postmenopausal women.   
Interestingly, a previous study showed that in the patients with radiographic OA aged 50 years or older, the 
incidence of joint pain in females was higher than that in males. On the other hand, in patients younger than 50 years, 
the incidence of pain in males with radiographic knee OA was higher than that in females [5]. Another study 
demonstrated that the incidence of pain in female patients was higher than that in males even with the same 
radiographic OA grade as diagnosed using the Kellgren/Lawrence (K/L) grading system [6]. These results suggest 
that the postmenopausal condition in women aged 50 years or over involves an increase in joint pain due to OA, 
which might derive from a different mechanism from that in men. 
With regard to the pathological relationship between osteoporosis and OA, there have been a number of studies 
on the underlying mechanisms [7,8], with most which focused on pathological changes in subchondral bone 
metabolism and inflammatory changes in joints, which were shown to affect the induction of pain [9-11].  
We previously reported that a high bone turnover state under osteoporotic changes decreased the pain threshold 
in the limbs of ovariectomized (OVX) mice, which we used as a postmenopausal osteoporosis model [12-15] . We, 
therefore, hypothesized that a patient with osteoporosis would complain more strongly of joint pain due to OA under 
a high bone turnover state in comparison with a patient without osteoporosis, even one with the same radiographic 
OA grade.  
In this study, we established model mice with mild OA with accompanying osteoporotic changes by OVX, and 
evaluated whether the decreased pain threshold due to a high bone turnover state induced pain-like behaviors in the 
model mice.  
 
Materials and Methods 
Animals 
The present experiments were approved by the University Animal Care Committee of our institution (Approval 
number: 16-087) and were undertaken in accordance with the ethical guidelines of the National Institute of Health. 
Every effort was made to minimize animal suffering and the number of animals used. Experiments were conducted 
on 8-week-old female C57BL/6J mice weighing 20–25 g (Japan SLC, Hamamatsu, Japan). The mice were housed in 
a temperature-controlled room at 21 °C with a 12h light/dark cycle, and were given free access to food and water. 
The animals were anesthetized with pentobarbital (0.5ml/kg) and 5% isoflurane for experiments involving OVX and 
monosodium iodoacetate (MIA) joint injection. The animals were humanely sacrificed with an intraperitoneal 
injection of pentobarbital sodium (0.5 mg/kg) and inhalation of 5% isoflurane after completion of the experiments. 
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We used a total of 141 mice including controls (without OVX or MIA injection), osteoporosis mice (no MIA injection 
after OVX), OA mice (MIA injection without OVX) and OA with osteoporosis mice (MIA injection after OVX).  
 
Osteoporosis and OA model mice 
The 8-week-old mice were bilaterally ovariectomized to induce osteoporotic changes with a high bone turnover 
state as in our previous studies [12]. The sham operation was performed using the same surgical procedure as the 
OVX operation, apart from ovary removal. The OVX (n = 50) and sham (n = 51) surgeries were performed using a 
minimally invasive technique through a dorsal approach. The OVX mice showed a significant increase in bone 
resorption markers at 4 weeks, and a significant decrease in bone mineral density (BMD) and changes in micro-
architecture according to micro-computed tomography (µCT) analysis of the femur at 8 weeks after surgery [12].  
OA was induced by an injection of monosodium iodoacetate (MIA, Sigma-Aldrich, St. Louis, MO) into the left 
knee joint at 6 weeks after OVX (Supplementary Fig. 1). The doses of MIA were 0.01mg, 0.05mg and 0.1mg per 
10µl of sterile saline. The left knee joint received an injection of saline as a placebo treatment in control mice. The 
knee injections were performed through the patellar tendon with the knee fixed at 90 degrees flexion [16].  
 
Histological analysis of OA  
For evaluation of cartilage degeneration and joint synovitis, samples were obtained at 2, 6, and 10 weeks after the 
administration of MIA (8, 12 and 16 weeks after OVX) (Supplementary Fig. 1) and were fixed in 10% neutral 
buffered formalin for 3 days. In addition, the samples were decalcified in 0.5M ethylenediaminetetraacetic acid 
(EDTA) for 5 days, and embedded in Tissue-Tek O.C.T. Compound (Sakura Finetek, Torrance, CA, USA). Embedded 
samples were sectioned along the coronal plane at a thickness of 10µm. The sections of each femur and tibia were 
then stained with hematoxylin and eosin (H-E), and safranin-O. Slide images were captured using a Super Coolscan 
5000 ED system (Nikon, Tokyo, Japan). Cartilage degeneration was evaluated using the 2010 Osteoarthritis Research 
Society International (OARSI) score with a scale ranging from stage 0 (normal) to 6 (vertical clefts/erosion to the 
calcified cartilage extending over >75% of the joint surface) for both the tibial and femoral articular cartilage on the 
medial side of the coronal sections for a global score of 0 to 12 for the knee joint [17]. Joint synovitis was assessed 
using the synovitis score with a scale ranging from 0-1 (no synovitis) to 5-9 (high-grade synovitis) for the synovial 
cell layer, stroma cell density and inflammatory infiltrates [18]. The synovitis grade was evaluated at the lateral 
synovium of the ACL and PCL on the H-E stained coronal sections. The number of osteoclasts was counted in four 
randomly selected fields of subchondral bone per tibia with the observer blinded to the treatment regimen received 
by the mice as in our previous studies [19]. 
 
Evaluation of bone micro-architecture by micro-computed tomography (µCT) 
 The isolated proximal tibia samples at 6 weeks after the administration of MIA (12 weeks after OVX) 
(Supplementary Fig. 1) were scanned on a µCT system (ScanXmate-L090, Comscantecno, Yokohama, Japan) that 
was operated at a lamp voltage of 75kV and a current of 100mA using X sys FP Version 1.7 and coneCTexpressIV 
1.32 (Comscantecno) software. Samples were scanned at a magnification factor of 10.9 and a spatial resolution of 
9.171mm/pixel. Captured images were rendered using TRI/3D BON (Ratoc System Engineering Co., Ltd., Tokyo, 
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Japan) software. Osteoporotic evaluation was performed on the basis of bone volume ratio (BS/BV, 1mm), bone 
volume fraction (BV/TV, %), trabecular number (Tb. N, 1/mm) and trabecular separation (Tb. Sp, 1µm). 
 
Measurements of serum tartrate-resistant acid-phosphatase 5b (TRAP5b) levels  
Blood samples were collected at 6 weeks after the administration of MIA (12 weeks after OVX). The samples were 
centrifuged at 15000 ×g for 15 min at 4˚C and the supernatants were extracted for sample preparation. The TRAP5b 
values were measured using a mouse TRAP5b enzyme-linked immune sorbent assay kit (Immunodiagnostic Systems, 
London, UK) in accordance with the manufacturer’s recommendations. 
 
Assessment of pain-like behaviors 
Behavioral tests were performed prior and at 2, 4, 6, 7, 8, 9, 10, 11 and 12 weeks after OVX as in previous studies 
(Supplementary Fig. 1) [12,19]. In brief, to assess their mechanical withdrawal response (von Frey test), the mice 
were placed in plastic chambers above a wire mesh floor, which allowed full access to the hind-paw. A 1.34 g von 
Frey filament (Semmes-Weinstein Monofilaments, North Coast Medical Inc., San Jose, CA, USA) was used to 
produce mechanical tactile stimuli, which were applied to the middle area of the plantar surface of the left hind-paws. 
Each hind-paw was probed by 10 consecutive stimulations, while alternating between the right and left paws for each 
set [19]. This was repeated at least 5 times at intervals of at least 10 min and the final value was obtained from the 
average of the 5 measurements. Mechanical sensitivity was evaluated as the rate of withdrawal responses. Visible 
lifting of the stimulated hind limb was considered to be a withdrawal response [19,20]. Thermal nociceptive testing 
(paw-flick test) was conducted using an analgesimeter (Plantar test 7370, Ugo Basile, Italy). The mice were placed 
in plastic chambers (6 × 4 × 4 cm) and left unrestrained. Radiant heat was applied to the plantar surface of the left 
hind-paws until they were actively withdrawn by the animal. Paw withdrawal latency (PWL) was considered to be 
an index of the thermal nociceptive threshold, and a decrease in this measurement indicated thermal hyperalgesia. 
Light beam intensity was adjusted so that the basal PWL was 1-5s. The cut-off time was set at 15 s to avoid tissue 
damage [12]. The observer was blinded to the treatment regimen received by the mice. 
 
Evaluation of the expression of osteoblast and osteoclast differentiation regulators  
Mice were anesthetized by an intraperitoneal injection of pentobarbital and isoflurane and the right femurs were 
excised. The femurs were homogenized in 1ml TRIZOL reagent (Invitrogen, Carlsbad, CA) 10 times at 3,000 
rpm/30 s using a bead crusher (TITEC, Tokyo, Japan). The homogenates were then centrifuged at 15,000 × g for 15 
min at 4 ̊C and the supernatants were extracted. Total RNA was isolated from the whole femurs and reverse 
transcribed into cDNA by polymerase chain reaction (PCR) using an RNA PCR kit (PrimeScriptTM RT-PCR Kit; 
Takara Bio Inc., Tokyo, Japan) according to the manufacturer’s protocol. The following primers were used: for 
Gapdh, ACCACAGTCCATGCCATCAC (forward primer) and TCCACCACCCTGTTGCTGA (reverse primer); 
for Runx2, GCTTGATGACTCTAAACCTA (forward primer) and AAAAAGGGCCCAGTTCTGAA (reverse 
primer); for Osterix, AGGCACAAAGAAGCCATAC (forward primer) and AATGAGTGAGGGAAGGGT (reverse 
primer); for Osteocalcin, CTCACTCTGCTGGCCCTG (forward primer) and CCGTAGATGCGTTTGTAGGC 
(reverse primer); and for Rankl, GGTCGGGCAATTCTGAATT (forward primer) and 
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GGGAATTACAAAGTGCACCAG (reverse primer) [15,21]. Reactions were carried out by PCR as follows: for 
Gapdh; 30 cycles at 95˚ for 40s, 55˚ for 40 s and 72˚ for 40s; for Runx2; 35 cycles at 94˚ for 30s, 60˚ for 30s, and 
72˚ for 60s; for Osterix; 40cycle at 94˚ for 30s, 58˚ for 30s and 72˚ for 40s; for Osteocalcin; 35 cycles at 94˚ for 
30s, 62˚ for 30s and 72˚ 30s; and for Rankl; 35 cycles at 94˚ for 30s, 65˚ for 30s and 72˚ for 60s. The values of the 
target gene bands were normalized to the level of Gapdh gene expression in the same sample for semi-quantitative 
measurement. Values in graphs are the means ± SD obtained from 4 independent experiments. 
 
Administration of drugs 
Alendronate (0.02 mg/kg of body weight diluted in physiological saline) (ALN; Merck & Co. Inc., NJ), a potent 
anti-resorptive agent, was administered to the mice subcutaneously [12] once a day from 6 to 8 weeks after OVX 
(Supplementary Fig. 1). We also examined the effect of a Cox2 inhibitor (carprofen; Sigma–Aldrich Japan, Tokyo, 
Japan) on pain-like behaviors in the OA model mice. Carprofen (5mg/kg of body weight diluted in physiological 
saline) was administered to the mice subcutaneously [14] once a day for the same period as the administration of 
alendronate (Supplementary Fig. 1). 
 
Statistical analysis 
All data are presented as means ± standard deviations. To determine differences between groups, measurements 
were repeated at least three times for each sample, and the individual mean value was used for the statistical analysis. 
The statistical significance between 2 groups was determined using a Student's t-test, and that among 3 or more 
groups was determined using one-way analysis of variance (ANOVA) followed by Tukey's post-hoc test. Analyses 




Histological analysis of OA induced by MIA in OVX mice 
First, we observed cartilage degeneration in the joint after the administration of MIA at a dose of 0.01mg, 0.05mg, 
or 0.1mg per 10µl of sterile saline. Mild OA changes were induced at 18 weeks even by treatment with 0.01mg MIA 
(data not shown). Based on these results, we found that a dose as low as 0.01mg MIA induced mild OA changes at 
2, 6, and 10 weeks after MIA injection, which was recognized as a model of mild OA, with progressive and significant 
increases in the OARSI score (data not shown).  
The histological findings revealed the progression of cartilage degeneration at 2, 6 and 10 weeks after injection in 
the OA model mice independent of OVX (OA with osteoporosis) or not (OA). On the other hand, there were no 
significant histological changes in the control mice with (osteoporosis) or without OVX (control) (Fig. 1A).  
The OARSI scores in the OA (n = 4) and OA with osteoporosis (n = 4) mice were significantly higher at 2, 6 and 
10 weeks after MIA injection (8, 12 and 16 weeks after OVX) than in the control (n = 4) and osteoporosis (n = 4) 
mice, respectively. The scores increased in the OA and OA with osteoporosis mice in a time-dependent manner. There 
was no significant difference in the score between the OA and OA with osteoporosis mice, or between the control 
and osteoporosis mice (Fig. 1B). 
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The synovitis score was significantly increased at 2 weeks after MIA injection (8 weeks after OVX) compared to 
those in the control and osteoporosis mice, while there was no significant difference in the score between the OA (n 
= 4) and OA with osteoporosis (n = 4) mice, or between the control (n = 4) and osteoporosis (n = 4) mice 
(Supplementary Fig. 2). At 6 and 10 weeks (at 12 weeks and 16 weeks after OVX), there were no significant 
differences in synovitis score among the control, OA, osteoporosis and OA with osteoporosis mice (Supplementary 
Fig. 2). 
 
Serum tartrate-resistant acid-phosphatase 5b (TRAP5b) levels 
The serum level of TRAP-5b (U/L) was significantly increased in the osteoporosis (n = 4) and OA with osteoporosis 
(n = 4) mice in comparison with the control and OA mice (n = 4) (Fig. 1C). There was no significant difference in 
the serum level of TRAP5b between the control and OA mice or the osteoporosis and OA with osteoporosis mice 
(Fig. 1C). 
 
Osteoporotic changes in the model mice  
The BS/BV, BV/TV and Tb. N values were significantly lower and Tb. Sp value significantly higher in the 
osteoporosis (n = 4) and OA with osteoporosis (n = 4) mice than in the control mice (n = 4), as measured by µCT of 
the proximal tibial bone at 6 weeks after MIA injection (12 weeks after OVX) (Figs. 2A-E). In contrast, there were 
no significant differences in those values between the osteoporosis and OA with osteoporosis mice (Figs. 2A-E). 
 
Expression of osteoblast and osteoclast differentiation regulators 
We examined changes in the expression of osteoblast and osteoclast regulators at 6 weeks after MIA injection (12 
weeks after OVX). The expression levels of Runx2 (Figs. 3A and B), Osterix (Figs. 3A and C), and Rankl (Figs. 3A 
and E) were significantly increased in the osteoporosis (n = 4) and OA with osteoporosis mice (n = 4) in comparison 
with those in the control mice (n = 4). In contrast, there were no significant differences in the expression levels of 
these regulators between the osteoporosis and OA with osteoporosis mice. The expression levels of Osteocalcin (Figs. 
3A and D) in the osteoporosis and OA with osteoporosis mice tended to be increased in comparison with that in the 
control mice, although the difference was not statistically significant.  
 
Changes in pain-like behaviors 
The OA with osteoporosis mice (n = 5) revealed significant increases in pain-like behaviors on the von Frey test 
(Fig. 4A) and paw-flick test (Fig. 4B) at 1, 2, 3, 4, 5, and 6 weeks after MIA injection (7, 8, 9, 10, 11 and 12 weeks 
after OVX) compared with the OA mice (n = 5) (b, OA with osteoporosis versus OA; * p<0.05, ** p<0.01). The OA 
with osteoporosis mice (n = 5) also revealed significant increases in pain-like behaviors on the von Frey test (Fig. 
4A) and paw-flick test (Fig. 4B) at 1, 2, 3, 4, 5, and 6 weeks after MIA injection (7, 8, 9, 10, 11 and 12 weeks after 
OVX) compared with the osteoporosis mice (n = 5) (c, OA with osteoporosis versus osteoporosis; * p<0.05, ** 
p<0.01). The pain-like behaviors were significantly increased from 4 weeks after OVX in comparison with the control 
mice (n = 4). Within 3 weeks after MIA injection, the osteoporosis mice showed more severe pain-like behaviors 
with OA induction than did the osteoporosis mice without OA (Figs. 4A and B). On the other hand, there was no 
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significant increase in pain-like behaviors in the mice without osteoporosis during the same period compared with 
that in the control mice (Figs. 4A and B).    
 
Effects of bisphosphonate and Cox2 inhibitor (carprofen) on histological changes 
 The histological findings revealed that cartilage degeneration was observed in the OA and OA with osteoporosis 
mice regardless of treatment with alendronate (+ ALN) or carprofen (+ carprofen), or not (+ vehicle) in comparison 
with that in control mice at 6 weeks after MIA injection (12 weeks after OVX). The severity of cartilage degeneration 
was mild and no significant differences in of the scores were observed among those mice (Fig. 5). 
 
Effects of bisphosphonate and Cox2 inhibitor (carprofen) on pain-like behaviors 
Treatment with ALN for 2 weeks significantly improved pain-like behaviors on the von Frey test (Fig. 6A) and 
paw-flick test (Fig. 6B) in the OA with osteoporosis mice (c, OA with osteoporosis + ALN versus OA with 
osteoporosis + vehicle, * p<0.05, ** p<0.01, n = 5), the values for which improved to similar levels to those in the 
control mice (n = 5). In addition, these effects were maintained for more than 4 weeks, even after the discontinuation 
of ALN treatment (Figs. 6A and B). On the other hand, ALN treatment had no significant effect in improving pain-
like behaviors in the OA mice (b, OA + ALN versus OA + vehicle, n = 5, respectively) (Figs. 6A and B).  
We evaluated the anti-inflammatory effects on pain-like behaviors in the OA and OA with osteoporosis mice by 
the administration of a Cox2 inhibitor (carprofen) for 2 weeks. Carprofen significantly improved pain-like behaviors 
in the OA and OA with osteoporosis mice; however, these effects were only partial and were limited to the 2 weeks 
of the drug administration period (b, OA + vehicle versus OA + carprofen; c, OA with osteoporosis + vehicle versus 
OA with osteoporosis + carprofen, * p<0.05, ** p<0.01, n = 6, respectively) (Figs. 6C and D).  
 
Effects of bisphosphonate and Cox2 inhibitor (carprofen) on osteoblast and osteoclast differentiation 
We examined the effects of ALN and carprofen on the number of osteoclasts in the subchondral field of the 
proximal tibia and the expression of osteoblast and osteoclast differentiation regulators in the OA mice with or 
without osteoporosis at 6 weeks after MIA injection (12 weeks after OVX). The number of osteoclasts (Fig. 7A) was 
significantly increased in the OA with osteoporosis mice (n = 4, ** p<0.01) in comparison with that in the control 
and OA mice (n = 4). ALN significantly inhibited the increase in the number of osteoclasts in the OA with 
osteoporosis mice (n = 4, ** p<0.01). On the other hand, there was no significant effect of ALN on the number of 
osteoclasts in the OA mice (Fig. 7A). The expression levels of Runx2 (Figs. 7B and C), Osterix (Figs. 7B and D) and 
Rankl (Figs. 7B and F) were significantly increased in the OA with osteoporosis mice (n = 4, * p<0.05, ** p<0.01) 
in comparison with those in the control mice (n = 4). ALN significantly inhibited the expression levels of those 
regulators in the OA with osteoporosis mice (n = 4). The expression of Osteocalcin (Figs. 7B and E) also tended to 
be increased in the OA with osteoporosis mice and inhibited by ALN treatment, although these changes were not 
statistically significant. On the other hand, the expression levels of those regulators were not significantly changed 
in the OA mice (n = 4) in comparison with those in the control mice, and they were not affected by ALN treatment 
(n = 4). Carprofen had no significant effect on the number of osteoclasts or the expression levels of those regulators 
in the OA mice with and without osteoporosis (Fig. 7).  
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Discussion 
OA is a major skeletal disease that progressively worsens over time with articular cartilage degradation, and the 
major source of disability for patients with OA is skeletal pain [22]. Previous studies demonstrated that the causes of 
pain in the pathophysiology of OA were related to increases in cytokines, chemokines and inflammatory factors in 
the synovium [10,11], changes in the metabolism of subchondral bone tissue [10,11], and bone marrow edema [9,10]. 
In addition, a recent study showed that the high metabolic activity of bone marrow lesions was associated with pain 
in patients with OA [23].  
Our previous studies demonstrated that a high bone turnover state under osteoporotic changes involves a decrease 
in the threshold of pain-like behaviors and a significant relationship between bone resorption maker levels and pain 
threshold values in osteoporosis model mice. We also showed one of the mechanisms for the decrease in the pain 
threshold is the formation of an acidic microenvironment, with the increased expression of ATP and inflammatory 
cytokines stimulating nociceptors, such as transient receptor potential channel vanilloid subfamily member 1 
(TRPV1), acid-sensing ion channels (ASICs) and P2X [12, 14, 15, 19, 21], in the bone tissue. We, then, speculated 
that the decreased threshold of skeletal pain due to those pathophysiological changes under osteoporotic changes 
could affect the induction of joint pain due to OA. 
In the present study, we established mild OA model mice through the injection of low-dose (0.01mg/10µl) MIA 
into the joint, and showed that the pain-like behaviors in the OA mice accompanying a high bone turnover state under 
osteoporotic changes were significantly increased in comparison with those in mice without the osteoporotic changes. 
Additionally, in the early phase (within 3 weeks) after MIA injection, we did not find any significant increase in the 
pain-like behaviors in the mild OA model mice without the osteoporotic changes in comparison with those in the 
control mice. On the other hand, the OA mice with a high bone turnover state under the osteoporotic change revealed 
a significant increase in pain-like behaviors even within 3 weeks after MIA injection compared with the osteoporosis 
model mice. Interestingly, there was no significant difference in the OA grade or severity of synovitis between the 
mice with and without the osteoporotic changes. These results indicated that a high bone turnover state under 
osteoporotic changes could significantly decrease the pain threshold in mice even when pathological OA changes 
were mild. We, therefore, believe that the decrease in the pain threshold due to a high bone turnover state might be 
one of mechanisms by which the pathophysiological changes under osteoporosis affects the induction of skeletal pain 
in patients with OA. Furthermore, this mechanism could explain why postmenopausal female patients had more 
severe pain than did male patients, even when they had the same radiographic OA grade [5,6]. 
Previous studies indicated that pathological changes in the subchondral bone due to osteoporosis was involved in 
the progression of OA and induction of pain [10,11]. In this study, we used a milder OA model compared with the 
previous studies [16,24], in which histopathological lesions could be mainly limited to the articular cartilage. In 
addition, the severity of the degenerative changes in those lesions in the OA mice with osteoporotic change did not 
significantly differ from that in the mice without that. We, therefore, believed that the decrease in the pain threshold 
due to a high bone turnover state under osteoporotic changes was a significant factor in the enhancement of pain-like 
behaviors even in the mild OA model mice. 
A number of studies reported the effects of bisphosphonate, a potent anti-bone resorption agent, on improvement 
in pain among OA patients through the regulation of subchondral bone metabolism, cartilage degradation, and bone 
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marrow lesions [25-28]; however, a certain mechanism underlying this effect remains unknown [25,26]. In this study, 
we did not find that bisphosphonate had any significant effect on the pain-like behaviors of the mild OA model mice 
without osteoporotic changes. We think that one reason for these contradictory results concerning the effect of 
bisphosphonate might be due to the mildness of the OA in our mouse model, with the subchondral bone lesions 
undergoing only mild pathological changes compared with those in the previous study, although we did not evaluate 
the pathohistological changes in the subchondral bone. On the other hand, in the OA model mice with osteoporotic 
changes, bisphosphonate markedly improved the pain-like behaviors accompanied with improvement in the high 
bone turnover state. Our previous studies demonstrated that bisphosphonate improved the threshold of pain-like 
behaviors through restoration of the high bone turnover state in osteoporosis model mice [12,14,15]. Based on these 
findings, we speculated that bisphosphonate might more effectively improve skeletal pain in OA patients with 
osteoporosis in comparison with that in patients without osteoporosis through improvement of the decreased pain 
threshold induced under a high bone turnover state.  
Interestingly, the effect of bisphosphonate on the pain-like behaviors in the OA mice with osteoporosis was 
markedly decreased to a level similar to that in the control mice; however, bisphosphonate had no significant effect 
on the behaviors in the OA mice without osteoporosis. A recent study demonstrated that activated osteoclasts in the 
subchondral bone of OA joints induced sensory innervation and skeletal pain [29]. Based on the results of that and 
our current study, we hypothesized that the activated osteoclasts in a high bone turnover state under osteoporotic 
changes might induce sensory innervation more intensively than in the absence of osteoporotic changes. Additionally, 
our previous studies reported that continuous nociceptive stimulation due to a high bone turnover condition could 
induce sensitization in osteoporosis model mice [12,14]. On the other hand, in our mild OA model mice without 
osteoporotic changes, we speculated that the sensory innervation and continuous nociceptive stimulation might have 
been absent due to subchondral bone osteoclasts not being activated. In this study, we demonstrated that the number 
of osteoclasts was significantly increased in the OA with osteoporosis mice in comparison with that in the control 
and OA mice. In addition, bisphosphonate significantly inhibited the increase in the number of osteoclasts in the OA 
with osteoporosis mice; however, it had no significant effect on that in the OA mice. Furthermore, the pain-like 
behaviors in the mild OA mice without osteoporosis might be mainly related to increases in cytokine, chemokine and 
inflammatory factor levels in the synovium [10,11]. Thus, bisphosphonate might markedly improve the pain-like 
behaviors in the OA model mice with osteoporotic changes to a level similar to that in the control mice, whereas 
bisphosphonate did not have an effect on the model mice without osteoporotic changes. However, this study did not 
provide sufficient results to support our hypothesis. Thus, further studies are needed to elucidate the mechanisms by 
which bisphosphonate more effectively improves the pain-like behaviors due to the pathophysiological changes 
related to OA under osteoporotic changes than that without the condition.   
   Several studies indicated that a decrease in estrogen due to OVX increases skeletal pain by augmenting the 
excitability of the nociceptive pathway in the nervous system [30,31], and that bisphosphonate might directly 
suppress the release of neurotransmitters or inflammatory mediators in the nervous system [32,33]. However, most 
of the administered bisphosphonate is taken up by bone tissue within 24 h and remains in the bone long term [34]. In 
addition, our study demonstrated that the effect of ALN on improving pain-like behaviors was maintained for more 
than 4 weeks, even after the discontinuation of ALN treatment. We, therefore, believe that the pain-like behaviors 
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associated with OVX or the improvement in those behaviors by treatment with ALN were likely to reflect an 
increased or improved bone turnover state, although we cannot rule out the direct suppressive effects of 
bisphosphonate on the nervous system. 
The present study had several limitations. First, the tests for pain-like behaviors such as the von Frey test and paw-
flick test have not yet been established as surrogate methods for measuring skeletal pain and were not focused on the 
knee pain, although those tests were used for the objective and quantitative assessment of changes in animal behaviors 
due to skeletal pain in a number of previous studies [35,36]. Second, we did not examine whether a high bone turnover 
state under osteoporotic changes affects the induction of pain-like behaviors in the advanced stage of OA, which 
presents with subchondral bone lesions. Third, we did not evaluate the effects of anti-resorptive agents other than 
ALN on pain-like behaviors in our OA model. Fourth, we did not examine the effects of treatment with 
bisphosphonate for periods longer than 14 days. Finally, we did not evaluate changes in anti-inflammatory cytokine 
expression in the joint or of several differentiation markers in the nerves. 
  In conclusion, we demonstrated that the pain-like behaviors in the mild OA model mice with a high bone turnover 
state under osteoporotic changes were significantly increased in comparison with the mild OA model mice without 
osteoporotic changes. In addition, bisphosphonate improved the pain-like behaviors in the OA mice with osteoporotic 
changes accompanied by suppression of the increases in bone metabolic markers. However, bisphosphonate had no 
significant effects on these parameters in the mild OA model mice without osteoporotic changes. Thus, we believe 
that a high bone turnover state affected the induction of pain-like behaviors due to the decreased threshold of skeletal 
pain in the mild OA model mice. 
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Figure 1. Histological analysis of cartilage degeneration and serum levels of tartrate-resistant acid-
phosphatase 5b (TRAP5b) in the model mice. 
Cartilage degeneration (arrows) was found at 2, 6 and 10 weeks after MIA injection (8, 12 and 16 weeks after 
OVX) (A). Right panels show higher magnification views of the boxed areas in the left panels. Bars in the left panels, 
500 µm; in the right panels, 100 µm. 
The Osteoarthritis Research Society International (OARSI) scores in OA (grey circles) and OA with osteoporosis 
(black squares) mice were significantly increased at 2, 6, 10 weeks after MIA injection in comparison with those in 
the control (white triangles) and osteoporosis (white rhombuses) mice (B).  ** p<0.01, OA versus control; †† p<0.01, 
OA with osteoporosis versus osteoporosis  
One-way analysis of variance followed by Tukey’s post hoc test. 
Control, no MIA injection without OVX; OA, MIA injection without OVX; osteoporosis, no MIA injection after 
OVX; OA with osteoporosis, MIA injection after OVX. 
The serum levels of TRAP5b was significantly increased in the osteoporosis and OA with osteoporosis mice 
compared with that in the control mice (C). There was no significant difference in the TRAP5b level between the 
osteoporosis and OA with osteoporosis mice.  
* p<0.05, versus control mice. One-way analysis of variance followed by Tukey’s post hoc test. 
The sham operation was performed in all control and OA mice. 
 
Figure 2. Osteoporotic changes in the model mice. 
The µCT findings (A-E) showed osteoporotic changes in the model mice. The BS/BV (B), BV/TV (C) and Tb. N 
(D) values in osteoporosis mice and OA with osteoporosis mice were significantly decreased and that of the Tb. Sp 
(E) significantly increased in comparison with those in control mice at 6 weeks after MIA injection (12 weeks after 
OVX). There were no significant differences in those values between the osteoporosis and OA with osteoporosis 
mice (B, C, D and E). * p<0.05, ** p<0.01; versus control mice 
 One-way analysis of variance followed by Tukey’s post hoc test.  
BS/BV, bone volume ratio (1mm); BV/TV, bone volume fraction (%); Tb. N, trabecular number (1/mm) and Tb. 
Sp, trabecular separation (1µm). 
The sham operation was performed in all control mice. 
 
Figure 3. Expression levels of Runx2, Osterix, Osteocalcin and Rankl in the femoral bone. 
The expression levels of Runx2 (A and B), Osterix (A and C), Osteocalcin (A and D) and Rankl (A and E) in the 
femoral bone were evaluated by semi-quantitative PCR analysis at 6 weeks after MIA injection (12 weeks after OVX). 
The expression levels of Runx2, Osterix and Rankl were significantly increased in the osteoporosis and OA with 
osteoporosis mice in comparison with the control mice, while no significant differences were observed between the 
osteoporosis and OA with osteoporosis mice. The expression levels are shown as the ratio of the gene of the interest 
to the control gene (Gapdh), and compared using those values.  
* p<0.05, versus control mice. One-way analysis of variance followed by Tukey’s post hoc test.  
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The sham operation was performed in all control mice. 
 
Figure 4. Assessment of pain-like behaviors. 
The pain-like behaviors on the von Frey test (A) and paw-flick test (B) after OVX and MIA injection 
 The OA mice (grey circles) showed significant increases in pain-like behaviors from 4 weeks after MIA injection 
(10 weeks after OVX) compared with the control mice (white triangles) (a; * p<0.05, ** p<0.01, versus control mice). 
The osteoporosis mice (white rhombuses, black squares) showed significant increases in pain-like behaviors from 4 
weeks after OVX (a; * p<0.05, ** p<0.01, versus control mice). The OA with osteoporosis (black squares) mice 
showed significant increases in pain-like behaviors from 1 week after MIA injection (7 weeks after OVX) in 
comparison with OA mice (grey circles) (b; ** p < 0.01, versus OA mice). The OA with osteoporosis mice (black 
squares) also showed significant increases from 1 week after MIA injection (7 weeks after OVX) in comparison with 
osteoporosis mice (white rhombuses) (c; * p<0.05, ** p<0.01, versus osteoporosis mice). One-way analysis of 
variance followed by Tukey’s post hoc test.  
The sham operation was performed in all control and OA mice. 
 
Figure 5. Effects of alendronate and Cox2 inhibitor (carprofen) on histological changes. 
 Histological features (arrows, cartilage degeneration) at lower (left) and higher (right) magnifications at 6 weeks 
after MIA injection (12 weeks after OVX). Bars in the left panels, 500 µm; in the right panels, 100 µm (A) 
The Osteoarthritis Research Society International (OARSI) scores in the OA and OA with osteoporosis mice were 
significantly increased independent of the treatment with alendronate or carprofen in comparison with the control 
mice. There was no significant difference in the OARSI score between the two groups of OA mice (B).  
** p<0.01, OA versus control mice. One-way analysis of variance followed by Tukey’s post hoc test.  
The sham operation was performed in all control and OA mice. 
 
Figure 6. Effects of alendronate (ALN) and Cox2 inhibitor (carprofen) on pain-like behaviors. 
Treatment with ALN (white squares) significantly improved pain-like behaviors on the von Frey test (A) and paw-
flick test (B) in the OA with osteoporosis mice (black squares), the values for which improved to levels similar to 
those in the control mice (white triangles). These effects were maintained for more than 4 weeks after the 
discontinuation of treatment (A, B). On the other hand, ALN (white circles) did not improve pain-like behaviors in 
the OA mice (grey circles) (A, B).  
Carprofen (white circles, white squares) significantly improved the pain-like behaviors in the OA and OA with 
osteoporosis mice (grey circles, black squares) (C, D). These changes were only partial and limited to the 2 weeks of 
drug administration (white circles, white squares). One-way analysis of variance followed by Tukey’s post hoc test. 
* p<0.05, ** p<0.01; a, versus control mice; b, versus OA mice; c, versus OA with osteoporosis mice + ALN and/or 
+ carprofen 




Figure 7. Effects of alendronate (ALN) and Cox2 inhibitor (carprofen) on the number of osteoclasts, and the 
expression levels of Runx2, Osterix, Osteocalcin and Rankl in the femoral bone in OA and OA with 
osteoporosis mice.  
The number of osteoclasts in the subchondral bone of the proximal tibia (A) and the expression levels of Runx2 (B, 
C), Osterix (B, D) and Rankl (B, F) in the femoral bone were significantly increased in the OA with osteoporosis 
mice (OA with osteoporosis + vehicle). Alendronate (OA with osteoporosis + ALN) significantly inhibited the 
number of that (A) and the expression levels of these regulators (C, D, F) in the mice (OA with osteoporosis + vehicle). 
In contrast, alendronate (OA + ALN) had no significant effect on the number of osteoclasts (A) and the expression 
levels of these regulators (C – F) in the OA mice (OA + vehicle). Carprofen had no significant effect on the number 
of osteoclasts or the expression in the OA mice with and without osteoporosis.  
The expression levels are shown as the ratio of the gene of the interest to the control gene (Gapdh), and compared 
using those values. One-way analysis of variance followed by Tukey’s post hoc test. * p<0.05, ** p<0.01 
The sham operation was performed in all control and OA mice. 
 
Supplementary Figure 1. Study design. 
 The 8-week-old mice were bilaterally ovariectomized (OVX), and monosodium iodoacetate (MIA) was 
administrated to the left knee joint at 6 weeks after OVX. Pain-like behaviors were assessed at 0, 2, 4, 6, 7, 8, 9, 10, 
11 and 12 weeks after OVX. Histological analysis was performed at 2, 6 and 10 weeks after MIA injection (8, 12 and 
16 weeks after OVX). Bone micro-architectural changes (as assessed by µCT), serum levels of TRAP5b, and the 
expression of osteoblast and osteoclast differentiation regulators were evaluated at 6 weeks after MIA injection (12 
weeks after OVX). Alendronate (ALN, 0.02 mg/kg of body weight) and Carprofen (5mg/kg of body weight) were 
administered to the mice subcutaneously once a day from 6 to 8 weeks after OVX.  
 
Supplementary Figure 2. Histological evaluation of synovitis in the model mice. 
Synovial tissue around the anterior cruciate ligament (ACL) and posterior cruciate ligament (PCL) (boxed area) 
was evaluated for lining cell layer, synovial stroma and inflammatory infiltrates (arrows) (A). The synovitis scores 
in the OA (grey circles) and OA with osteoporosis (black squares) mice were significantly higher at 2 weeks after 
MIA injection (8 weeks after OVX) than those in the control (white triangles) and osteoporosis (white rhombuses) 
mice. At 6 and 10 weeks after MIA injection (12 weeks and 16 weeks after OVX), there were no significant 
differences in the scores among the control, OA, osteoporosis and OA with osteoporosis mice (B). * p<0.05, OA 
versus control; † p<0.05, OA with osteoporosis versus osteoporosis by one-way analysis of variance followed by 
Tukey’s post hoc test.  
The sham operation was performed in all control and OA mice. 
Right panels show higher magnification views of the boxed areas in the left panels 















































































































































































Supplementary Fig. 2 
 
 
